ArticleJournal of orthopaedics2025
Relationship between RAR and the risk of osteoarthritis: a comprehensive analysis based on NHANES data (1999-2018).
Article in Journal of orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) is a prevalent disease characterized by the progressive loss of articular cartilage and chronic inflammation, contributing to an increasing epidemiological burden. While several risk factors have been identified, there remains a significant lack of reliable biomarkers for assessing OA risk. This study aims to investigate the association between the red blood cell distribution width to albumin ratio (RAR) and OA risk, as well as to evaluate its potential utility as a biomarker for OA risk assessment. Methods: We utilized data from the National Health and Nutrition Examination Survey (NHANES) to include a total of 35,902 participants, among whom 4,285 were diagnosed with OA. A weighted logistic regression model was employed to assess the association between different quartiles of RAR and OA risk, adjusting for relevant confounding factors. Additionally, we applied a restricted cubic spline (RCS) model to explore the non-linear dose-response relationship between RAR and OA risk, and conducted subgroup analyses to further elucidate this association. Results: RAR was significantly and positively associated with the risk of OA, with an odds ratio of 1.91 (95 % CI: 1.58-2.31, P = 5.31 × 10-10) for the highest quartile (Q4) in the weighted multivariate logistic regression model. This indicates a marked increase in OA risk with rising RAR levels. Furthermore, the relationship between RAR and OA was non-linear, and the effects of RAR exhibited significant heterogeneity across different populations. Conclusion: The level of RAR is positively correlated with OA risk, suggesting its potential as a biomarker for OA risk assessment. However, since causality cannot be established, further prospective or longitudinal studies are necessary to validate its clinical relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.